Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.
Prof Rory Johnson, Associate Professor, University College Dublin and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca, will lead this year’s event, focussed on ‘drugging the undruggable’.
Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.
The 2024 Bionow Awards dinner marked an exceptional evening of recognition and celebration, as 342 distinguished guests gathered at the Concorde Conference Centre on 6 March to honour those who have demonstrated outstanding ingenuity and dedication.
New Women in Biotech leadership report is first in comprehensively collecting and examining C-suite gender leadership data for UK biotech. The report identifies clear successes of female leadership at the same time as highlighting sustained challenges.
Precision BioSearch is proud to support the Pioneer Group Launch Accelerator Programme for the second consecutive year, equipping the UK and Ireland’s most promising biotech founders with the skills to build and scale high-performing teams.
As Donald Trump returns to the White House, the biotech industry is assessing what his presidency means for investment and innovation. With the UK’s life sciences sector gaining strength, could this be the moment to turn uncertainty into opportunity?
As we bid a fond farewell to Christiane Abouzeid after over 20 years of outstanding service to the BioIndustry Association, we are also thrilled to announce new leadership changes within our Policy and Public Affairs team.
Matthew has over 25 years’ experience in drug discovery and development across multiple target classes covering oncology, immunology, neurology, ophthalmology and metabolic disease. He joins from Storm Therapeutics — where he was Senior Vice President of Therapeutics.
Medicines Discovery Catapult (MDC), a national Life Sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its Executive team with the appointment of a Chief Commercial Officer and its first Managing Director.
Inaphaea BioLabs, the translational contract research organisation based at MediCity Nottingham, has announced the promotion of Melissa Barr to Head of Scientific Operations.
OMass Therapeutics Strengthens its Leadership Team with the Promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical
Stablepharma are delighted to announce that they have been selected to be part of Innovate UK’s prestigious Scaleup Programme, recognising the company's potential to grow exponentially and scale globally.
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Entia and is pleased to announce the placement of Timothy Broke-Smith as Senior Vice President of Partnerships.
Dr Mahony will work with the UK Government to champion investment into the UK’s innovative life sciences and biotech sector, including playing a key role in the ongoing pension reforms led by Chancellor Rachel Reeves MP.
OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO).
